Clinical Data

Cytokinetics heart drug scores in closely watched trial

BioPharma Dive

Myqorzo s success in non-obstructive hypertrophic cardiomyopathy separates it from Bristol Myers Squibb s rival Camzyos and opens up a multibillion-dollar market opportunity.

Cardiovascular

Read full story

pharminent May 5, 2026 (Last updated: May 5, 2026)

BioPharma Dive

Myqorzo s success in non-obstructive hypertrophic cardiomyopathy separates it from Bristol Myers Squibb s rival Camzyos and opens up a multibillion-dollar market opportunity.

Cardiovascular

Read full story

Related Stories

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

Summit shares descend as PD-1/VEGF asset misses early survival mark

You May Have Missed

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat

Cytokinetics heart drug scores in closely watched trial

Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point